FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Vet Parasitol / In vitro growth inhibition of Theileria equi by bumped kinas...
Veterinary parasitology2018; 251; 90-94; doi: 10.1016/j.vetpar.2017.12.024

In vitro growth inhibition of Theileria equi by bumped kinase inhibitors.

Abstract: Theileria equi, an etiologic agent of equine piroplasmosis, is a tick-transmitted hemoprotozoan of the phylum Apicomplexa. Recent outbreaks of piroplasmosis in the United States have renewed interest in safe and effective treatment options. Although imidocarb dipropionate (IMD) is the drug of choice for clearance of T. equi, adverse reactions and recently documented resistance support the need for alternative therapeutic strategies. The recently described bumped kinase inhibitors (BKIs) are a new class of compounds that could potentially be used as safe and effective alternatives to IMD. In an initial effort to evaluate this potential, herein we determined the T. equi growth inhibitory activity of 11 BKIs relative to that of IMD and the previously tested BKI 1294. Because some BKIs have known human ether-à-go-go related gene (hERG) channel activity, we also assessed the hERG activity of each compound with the goal to identify those with the highest potency against T. equi coupled with the lowest potential for cardiotoxicity. Results: Six BKIs inhibited T. equi growth in vitro, including the previously evaluated BKI 1294 which was used as a positive control. All six compounds were significantly less potent (higher 50% effective concentration (EC)) than IMD. Two of those compounds were more potent than BKI 1294 control but had similar hERG activity. Although the remaining three compounds had similar to lower potency than BKI 1294, hERG EC was higher for three of them (BKI 1735, BKI 1369 and BKI 1318). Conclusions: The BKI compounds evaluated in this study inhibited T. equi in vitro and had diverse hERG activity. Based on these considerations, three compounds would be suitable for further evaluation. While these results provide a foundation for future work, in vivo pharmacokinetic, pharmacodynamics, and safety studies are needed before BKI compounds can be recommended for clinical use in T. equi infected horses.
Copyright © 2018 Elsevier B.V. All rights reserved.
Get Full Text
Publication Date: 2018-01-01 PubMed ID: 29426483PubMed Central: PMC5959018DOI: 10.1016/j.vetpar.2017.12.024Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigates the effectiveness of a new class of compounds called bumped kinase inhibitors (BKIs) in inhibiting the growth of Theileria equi, a parasite that causes equine piroplasmosis. The research identified six BKIs which inhibited T. equi’s growth in vitro, though their effectiveness was less than the current treatment of choice, imidocarb dipropionate. Researchers further compared these BKIs to evaluate their potential cardiotoxicity, leading them to identify three as safe for further study.

Introduction to Theileria equi and the Need for New Treatment Options

  • The equine parasite Theileria equi is responsible for the disease equine piroplasmosis, which is transmitted by ticks.
  • Due to recent outbreaks in the United States, there’s an increased interest in finding safe and effective treatment options.
  • The drug currently used for treatment is imidocarb dipropionate (IMD). However, documented resistance and adverse reactions present a need for alternatives.

Bumped Kinase Inhibitors

  • The bumped kinase inhibitors (BKIs) are a new class of drugs that might be used as an alternative to IMD.
  • The study examines the effectiveness of 11 BKIs by comparing their ability to inhibit T. equi growth to IMD and a previously tested BKI.
  • The potential cardiotoxicity of the BKIs was assessed by evaluating their human ether-à-go-go related gene (hERG) channel activity.

Results

  • Six of the 11 BKIs tested inhibited T. equi growth in vitro, including the BKI used as a control group.
  • All six were less potent than IMD, implying they required higher concentrations to be effective.
  • Three BKIs showed similar to lower potency but higher hERG activity than the control BKI. High hERG activity indicates a potential risk of cardiotoxicity.

Conclusion and Further Steps

  • The study concludes that three BKI compounds could be suitable for further evaluation, as they showed potency against T. equi and acceptable hERG activity levels.
  • Before recommending these compounds for clinical use, the authors advise conducting further studies to assess factors such as pharmacokinetics, pharmacodynamics, and safety in vivo.

Cite This Article

APA
Gimenez F, Hines SA, Evanoff R, Ojo KK, Van Voorhis WC, Maly DJ, Vidadala RSR, Mealey RH. (2018). In vitro growth inhibition of Theileria equi by bumped kinase inhibitors. Vet Parasitol, 251, 90-94. https://doi.org/10.1016/j.vetpar.2017.12.024

Publication

Veterinary parasitology
ISSN: 1873-2550
NlmUniqueID: 7602745
Country: Netherlands
Language: English
Volume: 251
Pages: 90-94
PII: S0304-4017(17)30536-8

Researcher Affiliations

Gimenez, Fernanda
  • Department of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA, 99164, USA. Electronic address: fgimenez@vetmed.wsu.edu.
Hines, Siddra A
  • Veterinary Research and Development, Inc., Pullman, WA, 99163, USA.
Evanoff, Ryan
  • Department of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA, 99164, USA.
Ojo, Kayode K
  • Department of Medicine, Division of Allergy and Infectious Disease, Center for Emerging and Reemerging Infectious Disease (CERID), University of Washington, Seattle, WA, 98109, USA.
Van Voorhis, Wesley C
  • Department of Medicine, Division of Allergy and Infectious Disease, Center for Emerging and Reemerging Infectious Disease (CERID), University of Washington, Seattle, WA, 98109, USA; Department of Global Health, University of Washington, Seattle, WA, 98195, USA.
Maly, Dustin J
  • Department of Chemistry, University of Washington, Seattle, WA, 98195, USA; Department of Biochemistry, University of Washington, Seattle, WA, 98195, USA.
Vidadala, Rama S R
  • Department of Chemistry, University of Washington, Seattle, WA, 98195, USA.
Mealey, Robert H
  • Department of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, WA, 99164, USA.

MeSH Terms

  • Animals
  • Antiprotozoal Agents / pharmacology
  • Antiprotozoal Agents / therapeutic use
  • Babesiosis / drug therapy
  • Babesiosis / parasitology
  • Cattle
  • Horse Diseases / drug therapy
  • Horse Diseases / parasitology
  • Horses / parasitology
  • Humans
  • Imidocarb / analogs & derivatives
  • Imidocarb / pharmacology
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use
  • Theileria / drug effects
  • Theileria / growth & development
  • Theileriasis / drug therapy
  • Theileriasis / epidemiology

Grant Funding

  • R01 AI089441 / NIAID NIH HHS
  • R01 AI111341 / NIAID NIH HHS
  • R01 HD080670 / NICHD NIH HHS

References

This article includes 38 references
  1. Adams LG. Clinicopathological aspects of imidocarb dipropionate toxicity in horses.. Res Vet Sci 1981 Jul;31(1):54-61.
    pubmed: 7313320
  2. Bridal TR, Margulis M, Wang X, Donio M, Sorota S. Comparison of human Ether-à-go-go related gene screening assays based on IonWorks Quattro and thallium flux.. Assay Drug Dev Technol 2010 Dec;8(6):755-65.
    pubmed: 20658944doi: 10.1089/adt.2010.0267google scholar: lookup
  3. Castellanos-Gonzalez A, White AC Jr, Ojo KK, Vidadala RS, Zhang Z, Reid MC, Fox AM, Keyloun KR, Rivas K, Irani A, Dann SM, Fan E, Maly DJ, Van Voorhis WC. A novel calcium-dependent protein kinase inhibitor as a lead compound for treating cryptosporidiosis.. J Infect Dis 2013 Oct 15;208(8):1342-8.
    pmc: PMC3778970pubmed: 23878324doi: 10.1093/infdis/jit327google scholar: lookup
  4. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome.. Cell 1995 Mar 10;80(5):795-803.
    pubmed: 7889573doi: 10.1016/0092-8674(95)90358-5google scholar: lookup
  5. Doerig C, Billker O. A parasite calcium switch and Achilles' heel revealed.. Nat Struct Mol Biol 2010 May;17(5):541-3.
    pubmed: 20442739doi: 10.1038/nsmb0510-541google scholar: lookup
  6. Doerig C, Billker O, Pratt D, Endicott J. Protein kinases as targets for antimalarial intervention: Kinomics, structure-based design, transmission-blockade, and targeting host cell enzymes.. Biochim Biophys Acta 2005 Dec 30;1754(1-2):132-50.
    pubmed: 16271522doi: 10.1016/j.bbapap.2005.08.027google scholar: lookup
  7. Grause JF, Ueti MW, Nelson JT, Knowles DP, Kappmeyer LS, Bunn TO. Efficacy of imidocarb dipropionate in eliminating Theileria equi from experimentally infected horses.. Vet J 2013 Jun;196(3):541-6.
    pubmed: 23199699doi: 10.1016/j.tvjl.2012.10.025google scholar: lookup
  8. Gutman GA, Chandy KG, Grissmer S, Lazdunski M, McKinnon D, Pardo LA, Robertson GA, Rudy B, Sanguinetti MC, Stühmer W, Wang X. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels.. Pharmacol Rev 2005 Dec;57(4):473-508.
    pubmed: 16382104doi: 10.1124/pr.57.4.10google scholar: lookup
  9. Hines SA, Ramsay JD, Kappmeyer LS, Lau AO, Ojo KK, Van Voorhis WC, Knowles DP, Mealey RH. Theileria equi isolates vary in susceptibility to imidocarb dipropionate but demonstrate uniform in vitro susceptibility to a bumped kinase inhibitor.. Parasit Vectors 2015 Jan 20;8:33.
    pmc: PMC4311422pubmed: 25600252doi: 10.1186/s13071-014-0611-6google scholar: lookup
  10. Holbrook AA. Biology of equine piroplasmosis.. J Am Vet Med Assoc 1969 Jul 15;155(2):453-4.
    pubmed: 5816130
  11. Huang W, Ojo KK, Zhang Z, Rivas K, Vidadala RS, Scheele S, DeRocher AE, Choi R, Hulverson MA, Barrett LK, Bruzual I, Siddaramaiah LK, Kerchner KM, Kurnick MD, Freiberg GM, Kempf D, Hol WG, Merritt EA, Neckermann G, de Hostos EL, Isoherranen N, Maly DJ, Parsons M, Doggett JS, Van Voorhis WC, Fan E. SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1.. ACS Med Chem Lett 2015 Dec 10;6(12):1184-1189.
    pmc: PMC4677665pubmed: 26693272doi: 10.1021/acsmedchemlett.5b00319google scholar: lookup
  12. Hui R, El Bakkouri M, Sibley LD. Designing selective inhibitors for calcium-dependent protein kinases in apicomplexans.. Trends Pharmacol Sci 2015 Jul;36(7):452-60.
    pmc: PMC4485940pubmed: 26002073doi: 10.1016/j.tips.2015.04.011google scholar: lookup
  13. Johnson SM, Murphy RC, Geiger JA, DeRocher AE, Zhang Z, Ojo KK, Larson ET, Perera BG, Dale EJ, He P, Reid MC, Fox AM, Mueller NR, Merritt EA, Fan E, Parsons M, Van Voorhis WC, Maly DJ. Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity.. J Med Chem 2012 Mar 8;55(5):2416-26.
    pmc: PMC3306180pubmed: 22320388doi: 10.1021/jm201713hgoogle scholar: lookup
  14. Kappmeyer LS, Thiagarajan M, Herndon DR, Ramsay JD, Caler E, Djikeng A, Gillespie JJ, Lau AO, Roalson EH, Silva JC, Silva MG, Suarez CE, Ueti MW, Nene VM, Mealey RH, Knowles DP, Brayton KA. Comparative genomic analysis and phylogenetic position of Theileria equi.. BMC Genomics 2012 Nov 9;13:603.
    pmc: PMC3505731pubmed: 23137308doi: 10.1186/1471-2164-13-603google scholar: lookup
  15. Keyloun KR, Reid MC, Choi R, Song Y, Fox AMW, Hillesland HK, Zhang Z, Vidadala R, Merritt EA, Lau AOT, Maly DJ, Fan E, Barrett LK, Van Voorhis WC, Ojo KK. The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites.. Parasitology 2014 Sep;141(11):1499-1509.
    pmc: PMC4390295pubmed: 24927073doi: 10.1017/S0031182014000857google scholar: lookup
  16. Kiryu K, Machida N, Kashida Y, Yoshihara T, Amada A, Yamamoto T. Pathologic and electrocardiographic findings in sudden cardiac death in racehorses.. J Vet Med Sci 1999 Aug;61(8):921-8.
    pubmed: 10487232doi: 10.1292/jvms.61.921google scholar: lookup
  17. Lai O, Belloli C, Crescenzo G, Carofiglio V, Ormas P, Marangi O, Cagnardi P. Depletion and bioavailability of imidocarb residues in sheep and goat tissues.. Vet Hum Toxicol 2002 Apr;44(2):79-83.
    pubmed: 11931508
  18. Larson ET, Ojo KK, Murphy RC, Johnson SM, Zhang Z, Kim JE, Leibly DJ, Fox AM, Reid MC, Dale EJ, Perera BG, Kim J, Hewitt SN, Hol WG, Verlinde CL, Fan E, Van Voorhis WC, Maly DJ, Merritt EA. Multiple determinants for selective inhibition of apicomplexan calcium-dependent protein kinase CDPK1.. J Med Chem 2012 Mar 22;55(6):2803-10.
    pmc: PMC3336864pubmed: 22369268doi: 10.1021/jm201725vgoogle scholar: lookup
  19. Lyle CH, Uzal FA, McGorum BC, Aida H, Blissitt KJ, Case JT, Charles JT, Gardner I, Horadagoda N, Kusano K, Lam K, Pack JD, Parkin TD, Slocombe RF, Stewart BD, Boden LA. Sudden death in racing Thoroughbred horses: an international multicentre study of post mortem findings.. Equine Vet J 2011 May;43(3):324-31.
    pubmed: 21492210doi: 10.1111/j.2042-3306.2010.00164.xgoogle scholar: lookup
  20. Mehlhorn H, Schein E. Redescription of Babesia equi Laveran, 1901 as Theileria equi Mehlhorn, Schein 1998.. Parasitol Res 1998 Jun;84(6):467-75.
    pubmed: 9660136doi: 10.1007/s004360050431google scholar: lookup
  21. Meyer C, Guthrie AJ, Stevens KB. Clinical and clinicopathological changes in 6 healthy ponies following intramuscular administration of multiple doses of imidocarb dipropionate.. J S Afr Vet Assoc 2005 Mar;76(1):26-32.
    pubmed: 15900897doi: 10.4102/jsava.v76i1.390google scholar: lookup
  22. Murphy RC, Ojo KK, Larson ET, Castellanos-Gonzalez A, Perera BG, Keyloun KR, Kim JE, Bhandari JG, Muller NR, Verlinde CL, White AC Jr, Merritt EA, Van Voorhis WC, Maly DJ. Discovery of Potent and Selective Inhibitors of Calcium-Dependent Protein Kinase 1 (CDPK1) from C. parvum and T. gondii.. ACS Med Chem Lett 2010 Oct 14;1(7):331-335.
    pmc: PMC2992447pubmed: 21116453doi: 10.1021/ml100096tgoogle scholar: lookup
  23. Nagamune K, Moreno SN, Chini EN, Sibley LD. Calcium regulation and signaling in apicomplexan parasites.. Subcell Biochem 2008;47:70-81.
    pubmed: 18512342doi: 10.1007/978-0-387-78267-6_5google scholar: lookup
  24. Ojo KK, Eastman RT, Vidadala R, Zhang Z, Rivas KL, Choi R, Lutz JD, Reid MC, Fox AM, Hulverson MA, Kennedy M, Isoherranen N, Kim LM, Comess KM, Kempf DJ, Verlinde CL, Su XZ, Kappe SH, Maly DJ, Fan E, Van Voorhis WC. A specific inhibitor of PfCDPK4 blocks malaria transmission: chemical-genetic validation.. J Infect Dis 2014 Jan 15;209(2):275-84.
    pmc: PMC3873787pubmed: 24123773doi: 10.1093/infdis/jit522google scholar: lookup
  25. Ojo KK, Larson ET, Keyloun KR, Castaneda LJ, Derocher AE, Inampudi KK, Kim JE, Arakaki TL, Murphy RC, Zhang L, Napuli AJ, Maly DJ, Verlinde CL, Buckner FS, Parsons M, Hol WG, Merritt EA, Van Voorhis WC. Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors.. Nat Struct Mol Biol 2010 May;17(5):602-7.
    pmc: PMC2896873pubmed: 20436472doi: 10.1038/nsmb.1818google scholar: lookup
  26. Ojo KK, Pfander C, Mueller NR, Burstroem C, Larson ET, Bryan CM, Fox AM, Reid MC, Johnson SM, Murphy RC, Kennedy M, Mann H, Leibly DJ, Hewitt SN, Verlinde CL, Kappe S, Merritt EA, Maly DJ, Billker O, Van Voorhis WC. Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors.. J Clin Invest 2012 Jun;122(6):2301-5.
    pmc: PMC3366411pubmed: 22565309doi: 10.1172/JCI61822google scholar: lookup
  27. Ojo KK, Reid MC, Kallur Siddaramaiah L, Müller J, Winzer P, Zhang Z, Keyloun KR, Vidadala RS, Merritt EA, Hol WG, Maly DJ, Fan E, Van Voorhis WC, Hemphill A. Neospora caninum calcium-dependent protein kinase 1 is an effective drug target for neosporosis therapy.. PLoS One 2014;9(3):e92929.
    pmc: PMC3969379pubmed: 24681759doi: 10.1371/journal.pone.0092929google scholar: lookup
  28. Pedersen PJ, Thomsen KB, Olander ER, Hauser F, Tejada Mde L, Poulsen KL, Grubb S, Buhl R, Calloe K, Klaerke DA. Molecular Cloning and Functional Expression of the Equine K+ Channel KV11.1 (Ether à Go-Go-Related/KCNH2 Gene) and the Regulatory Subunit KCNE2 from Equine Myocardium.. PLoS One 2015;10(9):e0138320.
    pmc: PMC4574097pubmed: 26376488doi: 10.1371/journal.pone.0138320google scholar: lookup
  29. Pedroni MJ, Vidadala RS, Choi R, Keyloun KR, Reid MC, Murphy RC, Barrett LK, Van Voorhis WC, Maly DJ, Ojo KK, Lau AO. Bumped kinase inhibitor prohibits egression in Babesia bovis.. Vet Parasitol 2016 Jan 15;215:22-8.
    pmc: PMC4724059pubmed: 26790733doi: 10.1016/j.vetpar.2015.10.023google scholar: lookup
  30. Ribeiro IB, Câmara AC, Bittencourt MV, Marçola TG, Paludo GR, Soto-Blanco B. Detection of Theileria equi in spleen and blood of asymptomatic piroplasm carrier horses.. Acta Parasitol 2013 Jun;58(2):218-22.
    pubmed: 23666659doi: 10.2478/s11686-013-0127-9google scholar: lookup
  31. Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia.. Nature 2006 Mar 23;440(7083):463-9.
    pubmed: 16554806doi: 10.1038/nature04710google scholar: lookup
  32. Short MA, Clark CK, Harvey JW, Wenzlow N, Hawkins IK, Allred DR, Knowles DP, Corn JL, Grause JF, Hennager SG, Kitchen DL, Traub-Dargatz JL. Outbreak of equine piroplasmosis in Florida.. J Am Vet Med Assoc 2012 Mar 1;240(5):588-95.
    pubmed: 22332629doi: 10.2460/javma.240.5.588google scholar: lookup
  33. Tecles F, Cerón JJ. Determination of whole blood cholinesterase in different animal species using specific substrates.. Res Vet Sci 2001 Jun;70(3):233-8.
    pubmed: 11676619doi: 10.1053/rvsc.2001.0465google scholar: lookup
  34. Ueti MW, Mealey RH, Kappmeyer LS, White SN, Kumpula-McWhirter N, Pelzel AM, Grause JF, Bunn TO, Schwartz A, Traub-Dargatz JL, Hendrickson A, Espy B, Guthrie AJ, Fowler WK, Knowles DP. Re-emergence of the apicomplexan Theileria equi in the United States: elimination of persistent infection and transmission risk.. PLoS One 2012;7(9):e44713.
    pmc: PMC3435266pubmed: 22970295doi: 10.1371/journal.pone.0044713google scholar: lookup
  35. Ueti MW, Palmer GH, Kappmeyer LS, Statdfield M, Scoles GA, Knowles DP. Ability of the vector tick Boophilus microplus to acquire and transmit Babesia equi following feeding on chronically infected horses with low-level parasitemia.. J Clin Microbiol 2005 Aug;43(8):3755-9.
    pmc: PMC1233951pubmed: 16081906doi: 10.1128/JCM.43.8.3755-3759.2005google scholar: lookup
  36. Vidadala RS, Rivas KL, Ojo KK, Hulverson MA, Zambriski JA, Bruzual I, Schultz TL, Huang W, Zhang Z, Scheele S, DeRocher AE, Choi R, Barrett LK, Siddaramaiah LK, Hol WG, Fan E, Merritt EA, Parsons M, Freiberg G, Marsh K, Kempf DJ, Carruthers VB, Isoherranen N, Doggett JS, Van Voorhis WC, Maly DJ. Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis.. J Med Chem 2016 Jul 14;59(13):6531-46.
    pmc: PMC5100899pubmed: 27309760doi: 10.1021/acs.jmedchem.6b00760google scholar: lookup
  37. Wang Z, Li X, Su D, Li Y, Wu L, Wang Y, Wu W. Residue depletion of imidocarb in Swine tissue.. J Agric Food Chem 2009 Mar 25;57(6):2324-8.
    pubmed: 19243130doi: 10.1021/jf803251jgoogle scholar: lookup
  38. Wise LN, Kappmeyer LS, Mealey RH, Knowles DP. Review of equine piroplasmosis.. J Vet Intern Med 2013 Nov-Dec;27(6):1334-46.
    pubmed: 24033559doi: 10.1111/jvim.12168google scholar: lookup

Citations

This article has been cited 3 times.
  1. Onzere CK, Hulbert M, Sears KP, Williams LBA, Fry LM. Tulathromycin and Diclazuril Lack Efficacy against Theileria haneyi, but Tulathromycin Is Not Associated with Adverse Clinical Effects in Six Treated Adult Horses. Pathogens 2023 Mar 14;12(3).
    doi: 10.3390/pathogens12030453pubmed: 36986375google scholar: lookup
  2. Sears K, Knowles D, Dinkel K, Mshelia PW, Onzere C, Silva M, Fry L. Imidocarb Dipropionate Lacks Efficacy against Theileria haneyi and Fails to Consistently Clear Theileria equi in Horses Co-Infected with T. haneyi. Pathogens 2020 Dec 10;9(12).
    doi: 10.3390/pathogens9121035pubmed: 33321715google scholar: lookup
  3. Tirosh-Levy S, Gottlieb Y, Fry LM, Knowles DP, Steinman A. Twenty Years of Equine Piroplasmosis Research: Global Distribution, Molecular Diagnosis, and Phylogeny. Pathogens 2020 Nov 8;9(11).
    doi: 10.3390/pathogens9110926pubmed: 33171698google scholar: lookup
Subscribe to our newsletter
Join 99,030 horse owners like you who receive our email updates on horse health and nutrition.